{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:38:34Z","timestamp":1792787914055,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"German Research Foundation","award":["GRK 2543\/1"],"award-info":[{"award-number":["GRK 2543\/1"]}],"id":[{"id":"https:\/\/ror.org\/018mejw64","id-type":"ROR","asserted-by":"crossref"}]},{"name":"German Research Foundation","award":["INST 2388\/341 and INST 2388\/641"],"award-info":[{"award-number":["INST 2388\/341 and INST 2388\/641"]}],"id":[{"id":"https:\/\/ror.org\/018mejw64","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Martin Weiss, Faculty of Medicine of the Eberhard Karls University T\u00fcbingen","award":["IZKF 2018106"],"award-info":[{"award-number":["IZKF 2018106"]}],"id":[{"id":"https:\/\/ror.org\/03a1kwz48","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Faculty of Medicine of the Eberhard Karls University T\u00fcbingen","award":["243210 and 41700"],"award-info":[{"award-number":["243210 and 41700"]}],"id":[{"id":"https:\/\/ror.org\/03a1kwz48","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK 2543\/1"],"award-info":[{"award-number":["GRK 2543\/1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Plasma treated solutions (PTS) have emerged as a promising anticancer strategy due to their ability to generate reactive oxygen and nitrogen species (RONS) that induce oxidative stress and disrupt multiple cellular pathways. Despite increasing interest in plasma-based cancer therapies, the mechanisms underlying their effects in ovarian cancer remain incompletely understood. This study aimed to investigate the biological effects of plasma treated medium (PTM) in ovarian cancer models, focusing on cell viability, caspase 3\/7 activity, DNA damage, cell cycle progression, and mitochondrial metabolism. Methods: Three established ovarian cancer cell lines were treated with PTM to evaluate dose-dependent effects on cell viability using a resazurin assay. Apoptotic signaling was assessed by caspase 3\/7 activity assays. DNA damage was analyzed by immunofluorescence staining of \u03b3H2AX, while cell cycle alterations were evaluated using propidium iodide staining and flow cytometry. Mitochondrial metabolism was investigated using fluorescence lifetime imaging microscopy together with NADH and FAD autofluorescence imaging. In addition, patient-derived high-grade serous ovarian cancer cells isolated from ascites were analyzed as independent biological replicates to assess biological relevance. Results: PTM induced dose-dependent inhibition of cell viability with IC\n                    <jats:sub>50<\/jats:sub>\n                    values ranging from 1:4 to 1:1.1 PTM dilutions across the tested cell lines. PTM treatment triggered \u03b3H2AX-associated DNA damage, caspase 3\/7 activity, and dynamic alterations in cell cycle progression. Fluorescence lifetime imaging revealed significant reductions in free NADH and changes in protein-bound NADH and FAD, consistent with mitochondrial dysfunction. These metabolic alterations were accompanied by morphological changes from filamentous mitochondrial networks to punctate structures. Patient-derived ovarian cancer cells showed partial responses, primarily reflected in cell cycle modulation, highlighting both biological relevance and intercellular heterogeneity. Conclusions: PTM exerts multifactorial anticancer effects in ovarian cancer models by inducing DNA damage, caspase 3\/7 activity, cell cycle alterations, and mitochondrial dysfunction. These findings provide further insight into the biological effects of plasma-based cancer therapies and support the potential of plasma treated solutions as a novel therapeutic strategy for ovarian cancer.\n                  <\/jats:p>","DOI":"10.1186\/s12935-026-04461-6","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:32:04Z","timestamp":1790692324000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cold atmospheric plasma treated medium (PTM) induce antitumor effects in human ovarian cancer cells"],"prefix":"10.1186","volume":"26","author":[{"given":"Franziska","family":"Ke\u00dfler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Oelkrug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst","family":"Oberlechner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Andress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Y.","family":"Brucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A. Carvajal","family":"Berrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Schenke-Layland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"issue":"3","key":"4461_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I. u. a. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834 . PubMed PMID: 38572751.","journal-title":"CA Cancer J Clin"},{"key":"4461_CR2","doi-asserted-by":"publisher","unstructured":"Lheureux S, Gourley C, Vergote I, Oza AM. M\u00e4rz. Epithelial ovarian cancer. The Lancet. 23. 2019;393(10177):1240\u201353. https:\/\/doi.org\/10.1016\/S0140-6736(18)32552-2","DOI":"10.1016\/S0140-6736(18)32552-2"},{"issue":"5","key":"4461_CR3","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","volume":"20","author":"RE Bristow","year":"2002","unstructured":"Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 1 M\u00e4rz. 2002;20(5):1248\u201359. .1248 PubMed PMID: 11870167.","journal-title":"J Clin Oncol 1 M\u00e4rz"},{"issue":"6","key":"4461_CR4","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"A du Bois","year":"2009","unstructured":"du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour les Etudes des Cancers de l\u2019Ovaire (GINECO). Cancer 15 M\u00e4rz. 2009;115(6):1234\u201344. https:\/\/doi.org\/10.1002\/cncr.24149 . PubMed PMID: 19189349.","journal-title":"Cancer 15 M\u00e4rz"},{"issue":"2","key":"4461_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1159\/000522310","volume":"38","author":"PH Sugarbaker","year":"2022","unstructured":"Sugarbaker PH, Chang D. Incomplete Cytoreduction of Colorectal Cancer Peritoneal Metastases: Survival Outcomes by a Cytoreduction Score. Visc Med 23 Februar. 2022;38(2):99\u2013108. https:\/\/doi.org\/10.1159\/000522310.","journal-title":"Visc Med 23 Februar"},{"issue":"4","key":"4461_CR6","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. Cancer J Clin. 2018;68(4):284\u201396. https:\/\/doi.org\/10.3322\/caac.21456.","journal-title":"Cancer J Clin"},{"issue":"4","key":"4461_CR7","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","volume":"2","author":"BM Norquist","year":"2016","unstructured":"Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S. u. a. Inherited Mutations in Women with Ovarian Carcinoma. JAMA Oncol 1 April. 2016;2(4):482\u201390. https:\/\/doi.org\/10.1001\/jamaoncol.2015.5495 . PubMed PMID: 26720728; PubMed Central PMCID: PMC4845939.","journal-title":"JAMA Oncol 1 April"},{"issue":"2","key":"4461_CR8","first-page":"93","volume":"22","author":"AT Ali","year":"2023","unstructured":"Ali AT, Al-ani O, Al-ani F. Epidemiology and risk factors for ovarian cancer. Prz Menopauzalny Juni. 2023;22(2):93\u2013104. 10. 5114\/pm.2023.128661 PubMed PMID: 37674925; PubMed Central PMCID: PMC10477765.","journal-title":"Prz Menopauzalny Juni"},{"issue":"11","key":"4461_CR9","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1093\/jnci\/djae164","volume":"116","author":"G Zheng","year":"2024","unstructured":"Zheng G, Baandrup L, Wang J, Hertzum-Larsen R, Hannibal CG, Faber MT. u. a. Ovarian cancer risk factors in relation to family history. J Natl Cancer Inst 1 November. 2024;116(11):1767\u201374. https:\/\/doi.org\/10.1093\/jnci\/djae164.","journal-title":"J Natl Cancer Inst 1 November"},{"issue":"10","key":"4461_CR10","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.annonc.2021.07.004","volume":"32","author":"N Colombo","year":"2021","unstructured":"Colombo N, Ledermann JA. Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines. Annals Oncol 1 Oktober. 2021;32(10):1300\u20133. https:\/\/doi.org\/10.1016\/j.annonc.2021.07.004.","journal-title":"Annals Oncol 1 Oktober"},{"issue":"8","key":"4461_CR11","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/ijgc-2019-000682","volume":"29","author":"A Reuss","year":"2019","unstructured":"Reuss A, du Bois A, Harter P, Fotopoulou C, Sehouli J, Aletti G. u. a. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33\/AGO-OVAR OP7). Int J Gynecol Cancer Oktober. 2019;29(8):1327\u201331. https:\/\/doi.org\/10.1136\/ijgc-2019-000682 . PubMed PMID: 31420412.","journal-title":"Int J Gynecol Cancer Oktober"},{"issue":"2","key":"4461_CR12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.20517\/cdr.2022.13","volume":"5","author":"MJ Flynn","year":"2022","unstructured":"Flynn MJ, Ledermann JA. Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer. Cancer Drug Resist 12 Mai. 2022;5(2):424\u201335. https:\/\/doi.org\/10.20517\/cdr.2022.13 . PubMed PMID: 35800366; PubMed Central PMCID: PMC9255242.","journal-title":"Cancer Drug Resist 12 Mai"},{"issue":"46","key":"4461_CR13","doi-asserted-by":"publisher","first-page":"42885","DOI":"10.1021\/acsami.9b13221","volume":"11","author":"T Wenzel","year":"2019","unstructured":"Wenzel T, Carvajal Berrio DA, Daum R, Reisenauer C, Weltmann KD, Wallwiener D. u. a. Molecular Effects and Tissue Penetration Depth of Physical Plasma in Human Mucosa Analyzed by Contact- and Marker-Independent Raman Microspectroscopy. ACS Appl Mater Interfaces 20 November. 2019;11(46):42885\u201395. https:\/\/doi.org\/10.1021\/acsami.9b13221.","journal-title":"ACS Appl Mater Interfaces 20 November"},{"key":"4461_CR14","doi-asserted-by":"publisher","unstructured":"Wenzel T, Carvajal Berrio DA, Reisenauer C, Layland S, Koch A, Wallwiener D. Januar, Trans-Mucosal Efficacy of Non-Thermal Plasma Treatment on Cervical Cancer Tissue and Human Cervix Uteri by a Next Generation Electrosurgical Argon Plasma Device. Cancers (Basel). 22. 2020;12(2):267. https:\/\/doi.org\/10.3390\/cancers12020267 PubMed PMID: 31979067; PubMed Central PMCID: PMC7072402.","DOI":"10.3390\/cancers12020267"},{"key":"4461_CR15","doi-asserted-by":"publisher","unstructured":"Weiss M, Arnholdt M, Hi\u00dfnauer A, Fischer I, Sch\u00f6nfisch B, Andress J. u. a. Tissue-preserving treatment with non-invasive physical plasma of cervical intraepithelial neoplasia\u2014a prospective controlled clinical trial. Front Med 15 August. 2023;10. https:\/\/doi.org\/10.3389\/fmed.2023.1242732.","DOI":"10.3389\/fmed.2023.1242732"},{"key":"4461_CR16","doi-asserted-by":"publisher","unstructured":"Henes M, Matovina S, Rottscholl R, Feng YS, Fleischhacker A, Wang G. u. a. Tissue preserving non-invasive physical plasma treatment for cervical squamous intraepithelial neoplasia grade 3\u2014a prospective randomized, controlled clinical trial. Front Med 7 November. 2025;12. https:\/\/doi.org\/10.3389\/fmed.2025.1669933.","DOI":"10.3389\/fmed.2025.1669933"},{"key":"4461_CR17","doi-asserted-by":"crossref","unstructured":"Dai X, Bazaka K, Thompson EW, Ostrikov KK. November. Cold Atmospheric Plasma: A Promising Controller of Cancer Cell States. Cancers (Basel). 13. 2020;12(11):3360. doi:10.3390\/cancers12113360 PubMed PMID: 33202842; PubMed Central PMCID: PMC7696697.","DOI":"10.3390\/cancers12113360"},{"key":"4461_CR18","doi-asserted-by":"publisher","unstructured":"Semmler ML, Bekeschus S, Sch\u00e4fer M, Bernhardt T, Fischer T, Witzke K. u. a. Molecular Mechanisms of the Efficacy of Cold Atmospheric Pressure Plasma (CAP) in Cancer Treatment. Cancers 22 Januar. 2020;12(2). https:\/\/doi.org\/10.3390\/cancers12020269.","DOI":"10.3390\/cancers12020269"},{"key":"4461_CR19","doi-asserted-by":"publisher","unstructured":"Marzi J, Stope MB, Henes M, Koch A, Wenzel T, Holl M. April, Noninvasive Physical Plasma as Innovative and Tissue-Preserving Therapy for Women Positive for Cervical Intraepithelial Neoplasia. Cancers (Basel). 12. 2022;14(8):1933. https:\/\/doi.org\/10.3390\/cancers14081933 PubMed PMID: 35454839; PubMed Central PMCID: PMC9027888.","DOI":"10.3390\/cancers14081933"},{"key":"4461_CR20","doi-asserted-by":"publisher","first-page":"1631530","DOI":"10.3389\/fimmu.2025.1631530","volume":"16","author":"G Wang","year":"2025","unstructured":"Wang G, Arnholdt M, Koch A, Enderle MD, Hahn M, Brucker SY. u. a. Non-invasive physical plasma activates stimulator of interferon genes pathway in triple negative breast cancer and is associated with increased host immune response. Front Immunol 24 Juli. 2025;16:1631530. https:\/\/doi.org\/10.3389\/fimmu.2025.1631530 . PubMed PMID: 40777006; PubMed Central PMCID: PMC12328447.","journal-title":"Front Immunol 24 Juli"},{"issue":"12","key":"4461_CR21","doi-asserted-by":"publisher","first-page":"6739","DOI":"10.21873\/anticanres.12133","volume":"37","author":"D Koensgen","year":"2017","unstructured":"Koensgen D, Besic I, G\u00fcmbel D, Kaul A, Weiss M, Diesing K. u. a. Cold Atmospheric Plasma (CAP) and CAP-Stimulated Cell Culture Media Suppress Ovarian Cancer Cell Growth - A Putative Treatment Option in Ovarian Cancer Therapy. Anticancer Res Dezember. 2017;37(12):6739\u201344. https:\/\/doi.org\/10.21873\/anticanres.12133 . PubMed PMID: 29187451.","journal-title":"Anticancer Res Dezember"},{"issue":"7","key":"4461_CR22","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1021\/acsaenm.5c00400","volume":"3","author":"F Ke\u00dfler","year":"2025","unstructured":"Ke\u00dfler F, Chuchuy J, Renner M, Lutz T, Decool H, Brucker SY. u. a. Scalable and Continuous Generation of Plasma-Treated Solutions Designed for Healthcare Applications. ACS Appl Eng Mater 25 Juli. 2025;3(7):2199\u2013210. https:\/\/doi.org\/10.1021\/acsaenm.5c00400.","journal-title":"ACS Appl Eng Mater 25 Juli"},{"key":"4461_CR23","doi-asserted-by":"publisher","first-page":"36282","DOI":"10.1038\/srep36282","volume":"6","author":"H Tanaka","year":"2016","unstructured":"Tanaka H, Nakamura K, Mizuno M, Ishikawa K, Takeda K, Kajiyama H. u. a. Non-thermal atmospheric pressure plasma activates lactate in Ringer\u2019s solution for anti-tumor effects. Sci Rep 8 November. 2016;6:36282. https:\/\/doi.org\/10.1038\/srep36282 . PubMed PMID: 27824103; PubMed Central PMCID: PMC5099972.","journal-title":"Sci Rep 8 November"},{"key":"4461_CR24","unstructured":"Riss TL, Moravec RA, Niles AL, Duellman S, Benink HA, Worzella TJ et al. Cell Viability Assays. In: Markossian S, Grossman A, Baskir H, Arkin M, Auld D, Austin C, Herausgeber. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004 [zitiert 6. M\u00e4rz 2026]. Verf\u00fcgbar unter: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK144065\/ PubMed PMID: 23805433."},{"issue":"5","key":"4461_CR25","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.3802\/jgo.2022.33.e83","volume":"33","author":"I Konishi","year":"2022","unstructured":"Konishi I, Abiko K, Hayashi T, Yamanoi K, Murakami R, Yamaguchi K. u. a. Peritoneal dissemination of high-grade serous ovarian cancer: pivotal roles of chromosomal instability and epigenetic dynamics. J Gynecol Oncol 22 August. 2022;33(5):e83. https:\/\/doi.org\/10.3802\/jgo.2022.33.e83 . PubMed PMID: 36032027; PubMed Central PMCID: PMC9428305.","journal-title":"J Gynecol Oncol 22 August"},{"key":"4461_CR26","first-page":"21","volume":"558","author":"B Paruchuri","year":"2025","unstructured":"Paruchuri B, Miller A. Gynecologic Cancers: Ovarian Cancer. FP Essent November. 2025;558:21\u20135. PubMed PMID: 41252823.","journal-title":"FP Essent November"},{"issue":"9","key":"4461_CR27","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1038\/bjc.2011.386","volume":"105","author":"M Keidar","year":"2011","unstructured":"Keidar M, Walk R, Shashurin A, Srinivasan P, Sandler A, Dasgupta S. u. a. Cold plasma selectivity and the possibility of a paradigm shift in cancer therapy. Br J Cancer 25 Oktober. 2011;105(9):1295\u2013301. https:\/\/doi.org\/10.1038\/bjc.2011.386 . PubMed PMID: 21979421; PubMed Central PMCID: PMC3241555.","journal-title":"Br J Cancer 25 Oktober"},{"issue":"12","key":"4461_CR28","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/ppap.201400068","volume":"11","author":"DB Graves","year":"2014","unstructured":"Graves DB. Reactive Species from Cold Atmospheric Plasma: Implications for Cancer Therapy. Plasma Processes Polym. 2014;11(12):1120\u20137. https:\/\/doi.org\/10.1002\/ppap.201400068.","journal-title":"Plasma Processes Polym"},{"issue":"14","key":"4461_CR29","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.3390\/cancers14143461","volume":"14","author":"R Limanowski","year":"2022","unstructured":"Limanowski R, Yan D, Li L, Keidar M. Preclinical Cold Atmospheric Plasma Cancer Treatment. Cancers Januar. 2022;14(14):3461. https:\/\/doi.org\/10.3390\/cancers14143461.","journal-title":"Cancers Januar"},{"issue":"11","key":"4461_CR30","doi-asserted-by":"publisher","first-page":"e11487","DOI":"10.1016\/j.heliyon","volume":"8","author":"H Kobayashi","year":"2022","unstructured":"Kobayashi H. Recent advances in understanding the metabolic plasticity of ovarian cancer: A systematic review. Heliyon November. 2022;8(11):e11487. https:\/\/doi.org\/10.1016\/j.heliyon. .2022.e11487 PubMed PMID: 36406733; PubMed Central PMCID: PMC9668530.","journal-title":"Heliyon November"},{"issue":"7015","key":"4461_CR31","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nature03097","volume":"432","author":"MB Kastan","year":"2004","unstructured":"Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nat November. 2004;432(7015):316\u201323. https:\/\/doi.org\/10.1038\/nature03097.","journal-title":"Nat November"},{"issue":"9","key":"4461_CR32","doi-asserted-by":"publisher","first-page":"e70168","DOI":"10.1111\/exd.70168","volume":"34","author":"L Li","year":"2025","unstructured":"Li L, Zeng Z, Ma T, Hu B, Guo M, Wang Q. The Role of ROS-Mediated Mitochondrial Dysfunction in the Development of Malignant Melanoma. Exp Dermatol September. 2025;34(9):e70168. https:\/\/doi.org\/10.1111\/exd.70168 . PubMed PMID: 40990316; PubMed Central PMCID: PMC12459083.","journal-title":"Exp Dermatol September"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-026-04461-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04461-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04461-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:12:29Z","timestamp":1790741549000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-026-04461-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4461"],"URL":"https:\/\/doi.org\/10.1186\/s12935-026-04461-6","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"24 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was obtained from the patients for the collection and scientific use of ascites-derived cells in this study.","order":1,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Primary human ovarian cancer cells were isolated from ascites obtained from consenting patients undergoing surgery at the Department of Women\u2019s Health, University Hospital T\u00fcbingen. The scientific use of the tissue was approved by the Ethical Committee of the Medical Faculty of the Eberhard Karls University of T\u00fcbingen (approval numbers: 6492017BO2, approved 12 January 2018; 495\/2018BO2, approved 19 October 2018).","order":2,"name":"Ethics","label":"Institutional review board statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"330"}}